4.65
-2.31%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gyre Therapeutics
From its filings with the US Securities and Exchange Commission
Gyre Therapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GYRE. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $116.6m and net income of $9.9m. At that date it held total assets of $166.1m and shareholders' equity of $106.0m.
We are a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. We operate through our majority indirectly owned subsidiary, Gyre Pharmaceuticals, in the PRC, and through our U.S. operations headquartered in San Diego, California.
In the PRC, we have established a strong commercial and operational foundation in fibrotic diseases through the successful development and commercialization of ETUARY® (pirfenidone), which has generated consistent revenue and positioned us as a leading participant in the treatment of pulmonary fibrosis.
Fibrotic diseases affect large patient populations worldwide and involve complex, multi-stage biological processes driven by multiple molecular pathways. Given this complexity, therapies that modulate key profibrotic signaling pathways may offer meaningful clinical benefit; however, effective treatment may require targeting mechanisms across different stages of disease progression.
Building on our commercialization experience and infrastructure in the PRC, we have expanded our presence into the United States to advance the clinical development of our innovative pipeline, including F351 (Hydronidone), our lead product candidate for liver fibrosis.
Quoted from its 10-K, filed 13 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 12 Apr 2006
- Employees
- 618
- Website
- gyretx.com ↗
- Head office
- 12730 HIGH BLUFF DRIVE, SAN DIEGO, CA, 92130
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Ping ZhangExecutive Chairman of the Board, Interim Chief Executive Officer, since 2025
- Mr. Songjiang MaPresident, Director, since 2023$180,858
- Ms. Ruoyu ChenChief Financial Officer$650,516
- Mr. Weiguo YeChief Operating Officer$332,619
- Mr. Thomas EastlingDirector$248,603
- Dr. Dan WengDirector
- Mr. Gordon CarmichaelIndependent Director$436,030
- Dr. David EpsteinIndependent Director$427,016
- Mr. Rodney NussbaumIndependent Director$440,559
- Dr. Renate ParryIndependent Director$446,738
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 59
- Environment
- 59
- Social
- 99
- Governance
- 19
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- The company operates in the biotechnology sector with a focus on organ fibrosis.
- It has a diverse pipeline including Hydronidone and pirfenidone.
- The firm holds a controlling interest in Beijing Continent for China operations.
Weaknesses
- The employee count in the description is only seven full-time staff.
- The main product Hydronidone is still in development stages.
- The company faces risks from its reliance on specific disease targets.
Opportunities
- Pirfenidone is undergoing Phase 3 trials for several lung diseases.
- Expansion into diabetic kidney disease via Phase 1 trials is possible.
- Advancing F573 for acute-on-chronic liver failure offers new avenues.
Threats
- Competitors in the biotechnology industry may develop similar treatments.
- Regulatory hurdles could delay clinical trial progress significantly.
- Market acceptance of new therapies remains uncertain and volatile.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.